This nanodrug delivery system-based CAR-T therapy produced CD8+ CAR-T cells dramatically on days 14 to 21, and the number of CD8+ CAR-T cells was significantly decreased on days 35 to 90 after killing the tumor (Fig. 11I). The gene discussed is CD8A; the disease is neoplasm.